The DM Companion Logo The DM Companion

About Us & Clinical Disclaimer

Our Mission

The German Shepherd Degenerative Myelopathy Companion (GSD DM Companion) was founded to bridge the gap between complex veterinary neurology and the daily reality of caring for a dog with Degenerative Myelopathy (DM). Our portal is dedicated to providing GSD owners with peer-reviewed scientific facts, stage-appropriate rehabilitation programs, practical safety home modifications, and objective timeline guides.

We believe that while Degenerative Myelopathy is currently a non-curable condition, proactive management can significantly preserve mobility and quality of life, extending the happy time you share with your companion.

Veterinary Medical Disclaimer

IMPORTANT: PLEASE READ CAREFULLY.

All information, content, and materials available on this website are for educational and informational purposes only. The content is not intended to be, and must not be taken as, a substitute for professional veterinary advice, diagnosis, treatment, or clinical care.

Always consult your primary care veterinarian, a board-certified veterinary neurologist, or a licensed canine physical rehabilitation practitioner regarding any medical condition, changes in mobility, or treatment protocols for your dog. Never disregard professional veterinary advice or delay seeking treatment because of something you have read on this website.

The developer and contributors of GSD DM Companion are not responsible for any adverse effects, injuries, or outcomes resulting from the application of advice, exercises, home modifications, or product selections presented on this site.

Evidence-Based References

Our resources are compiled from peer-reviewed studies and veterinary clinical trials, including:

  • Research on SOD1 genetic testing and breed-specific penetrance in German Shepherd Dogs (Orthopedic Foundation for Animals).
  • Physiological trials evaluating the impact of daily structured physical therapy on longevity in canine DM patients (Kathmann et al., 2006).
  • Human ALS translational clinical studies testing the efficacy of neuroprotective compounds (e.g., Riluzole).